Illinois Municipal Retirement Fund Purchases 4,010 Shares of DaVita Inc. $DVA

Illinois Municipal Retirement Fund boosted its position in DaVita Inc. (NYSE:DVA) by 15.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,538 shares of the company’s stock after acquiring an additional 4,010 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in DaVita were worth $4,350,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. lifted its position in shares of DaVita by 7.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock worth $8,452,000 after buying an additional 4,048 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in DaVita in the first quarter valued at about $364,000. LPL Financial LLC raised its stake in DaVita by 36.2% during the first quarter. LPL Financial LLC now owns 18,689 shares of the company’s stock worth $2,859,000 after acquiring an additional 4,968 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of DaVita by 31.9% in the first quarter. Victory Capital Management Inc. now owns 57,074 shares of the company’s stock worth $8,731,000 after acquiring an additional 13,802 shares during the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of DaVita in the 1st quarter valued at approximately $513,000. 90.12% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DVA shares. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Bank of America decreased their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research note on Wednesday, September 10th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Barclays cut their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. Finally, TD Cowen lowered their target price on DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a report on Monday, November 3rd. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $148.00.

DaVita Trading Up 1.0%

Shares of DVA opened at $123.55 on Thursday. The company has a market capitalization of $8.72 billion, a PE ratio of 12.72, a PEG ratio of 0.91 and a beta of 1.13. The stock’s 50-day moving average price is $128.26 and its two-hundred day moving average price is $135.63. DaVita Inc. has a 12 month low of $115.39 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. During the same quarter last year, the firm posted $2.59 EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.